Pharmafile Logo

Cancer Research UK

- PMLiVE

Man Boobs campaign wins at D&AD Impact Awards

Takes home White Pencil in inaugural awards for creative contribution to society

Eli Lilly HQ

Lilly presses on with breast cancer study despite setback

CDK 4/6 inhibitor abemaciclib shows disappointing results in phase III trial

Novartis Gehry Building

FDA deems ribociclib a breast cancer breakthrough

Novartis looks to catch-up with Pfizer’s Ibrance with early approval in the US

Eli Lilly HQ

Lilly and Boehringer combine breast cancer drugs in trial

Firms anticipate together the two drugs will offer a “more complete pathway interference”

- PMLiVE

Biosimilar trastuzumab comparable to brand, ASCO hears

Roche’s Herceptin matched in safety and efficacy by Mylan and Biocon’s breast cancer drug

Novartis building

Novartis says Cosentyx is ‘outpacing competitors’

Claims new psoriasis drug has almost a third of the market share in Germany alone

Roche's Perjeta pertuzumab

NICE rejects Roche’s breast cancer drug Perjeta

Says the treatment's long-term benefits are unclear

Novartis day

Trial sets up showdown between Ibrance and Novartis’ ribociclib

Positive interim data could put the Swiss firm's breast cancer therapy in-line for early approval

- PMLiVE

Pharma trio join with top universities for new drug search

AZ, GSK and J&J join forces with Imperial, University College and Cambridge

Why is the UK lagging behind the rest of Europe in cancer survival?

Say Communications, London healthcare PR agency, discusses the latest technologies that will improve cancer survival rates in UK

Say Communications

Roche Basel Switzerland

Price cut keeps Kadcyla on CDF

Comes after pressure from campaign groups

Eli Lilly HQ

Lilly wins breakthrough designation for breast cancer drug

CDK 4 and 6 inhibitor Abemaciclib's development to be expedited by FDA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links